Trial Profile
A prospective, randomized, double-blind and placebo-controlled, parallel group, phase II study to compare the efficacy and safety of candesartan versus placebo on cognitive impairment associated with Parkinson's disease. Exploratory study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2022
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 18 Sep 2022 Results presented at the 26th International Congress of Parkinson's Disease and Movement Disorders
- 27 Jan 2019 Status changed from recruiting to completed.
- 30 Jun 2016 New trial record